ATE212859T1 - C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt - Google Patents

C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt

Info

Publication number
ATE212859T1
ATE212859T1 AT94929047T AT94929047T ATE212859T1 AT E212859 T1 ATE212859 T1 AT E212859T1 AT 94929047 T AT94929047 T AT 94929047T AT 94929047 T AT94929047 T AT 94929047T AT E212859 T1 ATE212859 T1 AT E212859T1
Authority
AT
Austria
Prior art keywords
esterase inhibitor
pct
myocardial infarction
inhibitor
acute myocardial
Prior art date
Application number
AT94929047T
Other languages
English (en)
Inventor
Willem Theodoor Hermens
Cornelis Erik Hack
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ATE212859T1 publication Critical patent/ATE212859T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94929047T 1993-09-01 1994-08-31 C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt ATE212859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93202572 1993-09-01
PCT/NL1994/000208 WO1995006479A1 (en) 1993-09-01 1994-08-31 Method to reduce myocardial injury during acute myocardial infarction

Publications (1)

Publication Number Publication Date
ATE212859T1 true ATE212859T1 (de) 2002-02-15

Family

ID=8214075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929047T ATE212859T1 (de) 1993-09-01 1994-08-31 C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt

Country Status (10)

Country Link
US (1) US6090777A (de)
EP (1) EP0716611B1 (de)
JP (2) JP4077030B2 (de)
AT (1) ATE212859T1 (de)
AU (1) AU678064B2 (de)
DE (1) DE69429816T2 (de)
DK (1) DK0716611T3 (de)
ES (1) ES2171465T3 (de)
PT (1) PT716611E (de)
WO (1) WO1995006479A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829014A1 (de) * 1998-06-30 2000-01-05 Centeon Pharma Gmbh Modifizierter C1-Esterase-Inhibitor zur Blockierung der Infektiosität von HIV
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
WO2008044928A1 (en) 2006-10-10 2008-04-17 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
EP3722320A3 (de) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-komplement-c1s-antikörper und verwendungen davon
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
ES2609070T3 (es) * 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
CA2901225C (en) * 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
KR102430453B1 (ko) * 2013-03-15 2022-08-05 바이로파마 바이오로직스 엘엘씨 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
US20160166660A1 (en) * 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
HK1259251A1 (zh) 2015-04-06 2019-11-29 Bioverativ Usa Inc. 人源化抗c1s抗体及其使用方法
MY198182A (en) 2016-10-12 2023-08-09 Bioverativ Usa Inc Anti-C1s Antibodies and Methods of use Thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
EP0497833A1 (de) * 1989-10-27 1992-08-12 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Muteine des c1-inhibitors und verwendungen dafür
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor

Also Published As

Publication number Publication date
AU7823994A (en) 1995-03-22
DK0716611T3 (da) 2002-05-21
EP0716611A1 (de) 1996-06-19
JP4077030B2 (ja) 2008-04-16
JPH09501946A (ja) 1997-02-25
ES2171465T3 (es) 2002-09-16
EP0716611B1 (de) 2002-02-06
PT716611E (pt) 2002-06-28
WO1995006479A1 (en) 1995-03-09
DE69429816T2 (de) 2002-09-19
DE69429816D1 (de) 2002-03-21
JP2008056705A (ja) 2008-03-13
US6090777A (en) 2000-07-18
AU678064B2 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
ATE212859T1 (de) C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
NZ223400A (en) Dental composition containing kappa-caseino-glycopeptides
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
BR9908280A (pt) Inibidores de enzimas de fosfolipase
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
DE69816280D1 (de) Inhibitoren des impdh-enzyms
EP0374440A3 (de) Hemmer der Lysyl-Oxydase
WO1995033464A3 (en) Retroviral protease inhibitor combinations
BR9714385A (pt) Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
BR9811594A (pt) Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
HU9204029D0 (en) Proteolytic enzym inhibitors
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
PL322576A1 (en) Transdermally administered therapeutic agent containing inhibitors of angiotensin convertase
EP0627925A4 (de) Trypsininhibitoren.
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
EP0985671A4 (de) PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
Wrenger et al. The N-terminal XX-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
MY120530A (en) Combination preparation for use in dementia
NO955258L (no) Medisinsk anvendelse av enzymer
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
ATE314481T1 (de) Promotor des transaldolase-genes von k.lactis und dessen verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification